Information Provided By: 
Fly News Breaks for May 22, 2017
PBYI
May 22, 2017 | 13:15 EDT
JPMorgan analyst Cory Kasimov is "incrementally more positive" on Puma Biotechnology ahead of Wednesday's FDA advisory panel. The analyst has an Overweight rating on the shares with an $89 price target. The tone and content of the documents are supportive of neratinib, Kasimov tells investors in a research note. The analyst says he's not overly concerned by the disclosure that the FDA advised Puma not to file in March 2016, since the meeting prompted a number of follow-up sensitivity analyses.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
